People · Operator
Named in public records as an officer, director or promoter · active 2016–2021 · Biotechnology, Other Energy
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Edgewise Therapeutics, Inc. | — | Biotechnology | Series C | $120.1M | $3.3B | 2019 |
| Neurogastrx, Inc. | — | Biotechnology | Series C | $80.0M | $1.7B | 2021 |
| Technicians for Sustainability, Inc. | — | Other Energy | Pre-Seed | $500K | $8.1M | 2016 |
KEVIN KOCH at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside KEVIN KOCH on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Peter Thompson | 1 | 16 |
| Jonathan Root | 1 | 16 |
| Aaron Royston | 1 | 7 |
| Klaus Veitinger | 1 | 6 |
| Kenneth Harrison | 1 | 4 |
| DAVID ALLISON | 1 | 3 |
| Paul Rogers | 1 | 2 |
| Nicole Koch | 1 | 1 |
| Rob McLane | 1 | 1 |
| David Stevenson | 1 | 1 |
| CYRIL DE COLLE | 1 | 1 |
| KLAUS VETTINGER | 1 | 1 |
| JAMES DETORE | 1 | 1 |
| JAMES O'MARA | 1 | 1 |
| Alan Russell | 1 | 1 |
| Travis Kendall | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.